Loading…
Extent of ST-segment resolution after fibrinolysis adds improved risk stratification to clinical risk score for ST-segment elevation myocardial infarction
Background The TIMI risk score (TRS) for ST-segment elevation myocardial infarction (STEMI) is a convenient validated clinical risk score for predicting mortality. Although not part of the risk score, ST-segment resolution (STRes) may provide a simple method of risk stratification based on the respo...
Saved in:
Published in: | The American heart journal 2010, Vol.159 (1), p.55-62 |
---|---|
Main Authors: | , , , , , , , , , |
Format: | Article |
Language: | English |
Subjects: | |
Citations: | Items that this one cites Items that cite this one |
Online Access: | Get full text |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
cited_by | cdi_FETCH-LOGICAL-c465t-66d310ae858b08ba9202b6c1bd57b1c1318e2a30b32c87bf221e1cacc95104723 |
---|---|
cites | cdi_FETCH-LOGICAL-c465t-66d310ae858b08ba9202b6c1bd57b1c1318e2a30b32c87bf221e1cacc95104723 |
container_end_page | 62 |
container_issue | 1 |
container_start_page | 55 |
container_title | The American heart journal |
container_volume | 159 |
creator | Harkness, James R., MD Sabatine, Marc S., MD, MPH Braunwald, Eugene, MD Morrow, David A., MD, MPH Sloan, Sarah, MS Wiviott, Stephen D., MD Giugliano, Robert P., MD, SM Antman, Elliott M., MD Cannon, Christopher P., MD Scirica, Benjamin M., MD, MPH |
description | Background The TIMI risk score (TRS) for ST-segment elevation myocardial infarction (STEMI) is a convenient validated clinical risk score for predicting mortality. Although not part of the risk score, ST-segment resolution (STRes) may provide a simple method of risk stratification based on the response to reperfusion. We sought to determine whether STRes provides incremental risk stratification to the TIMI risk score. Methods The Clopidogrel as Adjunctive Reperfusion Therapy—Thrombolysis in Myocardial Infraction (CLARITY-TIMI 28) trial randomized STEMI patients receiving fibrinolysis to clopidogrel or placebo. A total of 2,340 patients had electrocardiograms (ECGs) valid to calculate STRes at 90 minutes, which was defined as complete (>70%), partial (30%-70%), or no resolution (30%). TRS was defined as low (0-2), medium (3-4), and high (≥5). Clinical follow-up was through 30 days. Results were validated in 2,743 patients from the ExTRACT-TIMI 25 study. Results The degree of STRes at 90 minutes after fibrinolysis correlated in a stepwise fashion with death or heart failure (5.1% complete STRes, 8.9% partial STRes, 13.4% no STRes, P < .001). Furthermore, the degree of STRes provided a consistent and significant gradient of risk across all risk score categories (low, medium, or high) and significantly improved the discriminatory ability of TIMI risk score to predict death or heart failure (c-statistic 0.69 for TIMI risk score alone and 0.74 with STRes added to the model, P < .001). With the inclusion of STRes to the TIMI risk score, 913 patients (39%) were reclassified to higher or lower risk groups, and the net reclassification improvement (NRI) was highly significant ( P < .001). In the ExTRACT-TIMI 25 trial, addition of the STRes improved also the c-statistic ( P = .012) and NRI ( P < .001). Conclusions The extent of STRes based on routinely obtained ECGs is an independent predictor of death and heart failure when used together with the TIMI risk score and significantly improves the ability to risk stratify patients after fibrinolysis. |
doi_str_mv | 10.1016/j.ahj.2009.10.033 |
format | article |
fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_733622282</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S000287030900831X</els_id><sourcerecordid>3238257731</sourcerecordid><originalsourceid>FETCH-LOGICAL-c465t-66d310ae858b08ba9202b6c1bd57b1c1318e2a30b32c87bf221e1cacc95104723</originalsourceid><addsrcrecordid>eNp9ks1u1DAQxy0EotvCA3BBlhDqKcvYTpyskCqhqnxIlTi0SNwsxxmD0yQutrNiX4WnxWG3FPXAyZ7xb8Yz8x9CXjBYM2DyTb_W3_s1B9hkew1CPCIrBpu6kHVZPiYrAOBFU4M4Iscx9tmUvJFPyREHBvlWr8ivi58Jp0S9pVfXRcRv42IFjH6Yk_MT1TZhoNa1wU1-2EUXqe66SN14G_wWOxpcvKExBZ2cdUb_CUqemsFN2RwO78YHpNaHf3_BAbd7ftx5o0PnMu4mq4NZvM_IE6uHiM8P5wn58v7i-vxjcfn5w6fzd5eFKWWVCik7wUBjUzUtNK3ecOCtNKztqrplhgnWINcCWsFNU7eWc4bMaGM2FYOy5uKEnO7z5oZ-zBiTGl00OAx6Qj9HVQshOefNQr56QPZ-DlMuTrEKSsmYqMtMsT1lgo8xoFW3wY067BQDteimepV1U4tuiyvrlmNeHjLP7Yjd34g7oTLw-gDomKdqg56Mi_ccF1DyimXu7Z7DPLGtw6CicTgZ7FxAk1Tn3X_LOHsQfSfjDe4w3nerIlegrpYFW_YLNgCNYF_Fb769zJU</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1504611374</pqid></control><display><type>article</type><title>Extent of ST-segment resolution after fibrinolysis adds improved risk stratification to clinical risk score for ST-segment elevation myocardial infarction</title><source>ScienceDirect Journals</source><creator>Harkness, James R., MD ; Sabatine, Marc S., MD, MPH ; Braunwald, Eugene, MD ; Morrow, David A., MD, MPH ; Sloan, Sarah, MS ; Wiviott, Stephen D., MD ; Giugliano, Robert P., MD, SM ; Antman, Elliott M., MD ; Cannon, Christopher P., MD ; Scirica, Benjamin M., MD, MPH</creator><creatorcontrib>Harkness, James R., MD ; Sabatine, Marc S., MD, MPH ; Braunwald, Eugene, MD ; Morrow, David A., MD, MPH ; Sloan, Sarah, MS ; Wiviott, Stephen D., MD ; Giugliano, Robert P., MD, SM ; Antman, Elliott M., MD ; Cannon, Christopher P., MD ; Scirica, Benjamin M., MD, MPH</creatorcontrib><description>Background The TIMI risk score (TRS) for ST-segment elevation myocardial infarction (STEMI) is a convenient validated clinical risk score for predicting mortality. Although not part of the risk score, ST-segment resolution (STRes) may provide a simple method of risk stratification based on the response to reperfusion. We sought to determine whether STRes provides incremental risk stratification to the TIMI risk score. Methods The Clopidogrel as Adjunctive Reperfusion Therapy—Thrombolysis in Myocardial Infraction (CLARITY-TIMI 28) trial randomized STEMI patients receiving fibrinolysis to clopidogrel or placebo. A total of 2,340 patients had electrocardiograms (ECGs) valid to calculate STRes at 90 minutes, which was defined as complete (>70%), partial (30%-70%), or no resolution (30%). TRS was defined as low (0-2), medium (3-4), and high (≥5). Clinical follow-up was through 30 days. Results were validated in 2,743 patients from the ExTRACT-TIMI 25 study. Results The degree of STRes at 90 minutes after fibrinolysis correlated in a stepwise fashion with death or heart failure (5.1% complete STRes, 8.9% partial STRes, 13.4% no STRes, P < .001). Furthermore, the degree of STRes provided a consistent and significant gradient of risk across all risk score categories (low, medium, or high) and significantly improved the discriminatory ability of TIMI risk score to predict death or heart failure (c-statistic 0.69 for TIMI risk score alone and 0.74 with STRes added to the model, P < .001). With the inclusion of STRes to the TIMI risk score, 913 patients (39%) were reclassified to higher or lower risk groups, and the net reclassification improvement (NRI) was highly significant ( P < .001). In the ExTRACT-TIMI 25 trial, addition of the STRes improved also the c-statistic ( P = .012) and NRI ( P < .001). Conclusions The extent of STRes based on routinely obtained ECGs is an independent predictor of death and heart failure when used together with the TIMI risk score and significantly improves the ability to risk stratify patients after fibrinolysis.</description><identifier>ISSN: 0002-8703</identifier><identifier>EISSN: 1097-6744</identifier><identifier>DOI: 10.1016/j.ahj.2009.10.033</identifier><identifier>PMID: 20102867</identifier><identifier>CODEN: AHJOA2</identifier><language>eng</language><publisher>New York, NY: Mosby, Inc</publisher><subject>Adult ; Aged ; Angina pectoris ; Aspirin ; Biological and medical sciences ; Blood pressure ; Cardiology. Vascular system ; Cardiovascular ; Clinical outcomes ; Confidence Intervals ; Coronary Angiography ; Coronary Circulation - drug effects ; Coronary Circulation - physiology ; Coronary heart disease ; Diabetes ; Dose-Response Relationship, Drug ; Drug Administration Schedule ; Electrocardiography ; Female ; Fibrinolysis - drug effects ; Follow-Up Studies ; Heart ; Heart attacks ; Heart failure ; Humans ; Hypertension ; Male ; Medical imaging ; Medical sciences ; Middle Aged ; Mortality ; Myocardial Infarction - diagnosis ; Myocardial Infarction - drug therapy ; Myocardial Infarction - mortality ; Myocarditis. Cardiomyopathies ; Odds Ratio ; Platelet Aggregation Inhibitors - administration & dosage ; Probability ; Risk Assessment ; Severity of Illness Index ; Survival Analysis ; Thrombolytic Therapy - methods ; Ticlopidine - administration & dosage ; Ticlopidine - analogs & derivatives ; Time Factors ; Treatment Outcome ; Vascular Patency - drug effects ; Veins & arteries</subject><ispartof>The American heart journal, 2010, Vol.159 (1), p.55-62</ispartof><rights>Mosby, Inc.</rights><rights>2010 Mosby, Inc.</rights><rights>2015 INIST-CNRS</rights><rights>Copyright 2010 Mosby, Inc. All rights reserved.</rights><rights>Copyright Elsevier Limited Jan 2010</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c465t-66d310ae858b08ba9202b6c1bd57b1c1318e2a30b32c87bf221e1cacc95104723</citedby><cites>FETCH-LOGICAL-c465t-66d310ae858b08ba9202b6c1bd57b1c1318e2a30b32c87bf221e1cacc95104723</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,4024,27923,27924,27925</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=22304251$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/20102867$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Harkness, James R., MD</creatorcontrib><creatorcontrib>Sabatine, Marc S., MD, MPH</creatorcontrib><creatorcontrib>Braunwald, Eugene, MD</creatorcontrib><creatorcontrib>Morrow, David A., MD, MPH</creatorcontrib><creatorcontrib>Sloan, Sarah, MS</creatorcontrib><creatorcontrib>Wiviott, Stephen D., MD</creatorcontrib><creatorcontrib>Giugliano, Robert P., MD, SM</creatorcontrib><creatorcontrib>Antman, Elliott M., MD</creatorcontrib><creatorcontrib>Cannon, Christopher P., MD</creatorcontrib><creatorcontrib>Scirica, Benjamin M., MD, MPH</creatorcontrib><title>Extent of ST-segment resolution after fibrinolysis adds improved risk stratification to clinical risk score for ST-segment elevation myocardial infarction</title><title>The American heart journal</title><addtitle>Am Heart J</addtitle><description>Background The TIMI risk score (TRS) for ST-segment elevation myocardial infarction (STEMI) is a convenient validated clinical risk score for predicting mortality. Although not part of the risk score, ST-segment resolution (STRes) may provide a simple method of risk stratification based on the response to reperfusion. We sought to determine whether STRes provides incremental risk stratification to the TIMI risk score. Methods The Clopidogrel as Adjunctive Reperfusion Therapy—Thrombolysis in Myocardial Infraction (CLARITY-TIMI 28) trial randomized STEMI patients receiving fibrinolysis to clopidogrel or placebo. A total of 2,340 patients had electrocardiograms (ECGs) valid to calculate STRes at 90 minutes, which was defined as complete (>70%), partial (30%-70%), or no resolution (30%). TRS was defined as low (0-2), medium (3-4), and high (≥5). Clinical follow-up was through 30 days. Results were validated in 2,743 patients from the ExTRACT-TIMI 25 study. Results The degree of STRes at 90 minutes after fibrinolysis correlated in a stepwise fashion with death or heart failure (5.1% complete STRes, 8.9% partial STRes, 13.4% no STRes, P < .001). Furthermore, the degree of STRes provided a consistent and significant gradient of risk across all risk score categories (low, medium, or high) and significantly improved the discriminatory ability of TIMI risk score to predict death or heart failure (c-statistic 0.69 for TIMI risk score alone and 0.74 with STRes added to the model, P < .001). With the inclusion of STRes to the TIMI risk score, 913 patients (39%) were reclassified to higher or lower risk groups, and the net reclassification improvement (NRI) was highly significant ( P < .001). In the ExTRACT-TIMI 25 trial, addition of the STRes improved also the c-statistic ( P = .012) and NRI ( P < .001). Conclusions The extent of STRes based on routinely obtained ECGs is an independent predictor of death and heart failure when used together with the TIMI risk score and significantly improves the ability to risk stratify patients after fibrinolysis.</description><subject>Adult</subject><subject>Aged</subject><subject>Angina pectoris</subject><subject>Aspirin</subject><subject>Biological and medical sciences</subject><subject>Blood pressure</subject><subject>Cardiology. Vascular system</subject><subject>Cardiovascular</subject><subject>Clinical outcomes</subject><subject>Confidence Intervals</subject><subject>Coronary Angiography</subject><subject>Coronary Circulation - drug effects</subject><subject>Coronary Circulation - physiology</subject><subject>Coronary heart disease</subject><subject>Diabetes</subject><subject>Dose-Response Relationship, Drug</subject><subject>Drug Administration Schedule</subject><subject>Electrocardiography</subject><subject>Female</subject><subject>Fibrinolysis - drug effects</subject><subject>Follow-Up Studies</subject><subject>Heart</subject><subject>Heart attacks</subject><subject>Heart failure</subject><subject>Humans</subject><subject>Hypertension</subject><subject>Male</subject><subject>Medical imaging</subject><subject>Medical sciences</subject><subject>Middle Aged</subject><subject>Mortality</subject><subject>Myocardial Infarction - diagnosis</subject><subject>Myocardial Infarction - drug therapy</subject><subject>Myocardial Infarction - mortality</subject><subject>Myocarditis. Cardiomyopathies</subject><subject>Odds Ratio</subject><subject>Platelet Aggregation Inhibitors - administration & dosage</subject><subject>Probability</subject><subject>Risk Assessment</subject><subject>Severity of Illness Index</subject><subject>Survival Analysis</subject><subject>Thrombolytic Therapy - methods</subject><subject>Ticlopidine - administration & dosage</subject><subject>Ticlopidine - analogs & derivatives</subject><subject>Time Factors</subject><subject>Treatment Outcome</subject><subject>Vascular Patency - drug effects</subject><subject>Veins & arteries</subject><issn>0002-8703</issn><issn>1097-6744</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2010</creationdate><recordtype>article</recordtype><recordid>eNp9ks1u1DAQxy0EotvCA3BBlhDqKcvYTpyskCqhqnxIlTi0SNwsxxmD0yQutrNiX4WnxWG3FPXAyZ7xb8Yz8x9CXjBYM2DyTb_W3_s1B9hkew1CPCIrBpu6kHVZPiYrAOBFU4M4Iscx9tmUvJFPyREHBvlWr8ivi58Jp0S9pVfXRcRv42IFjH6Yk_MT1TZhoNa1wU1-2EUXqe66SN14G_wWOxpcvKExBZ2cdUb_CUqemsFN2RwO78YHpNaHf3_BAbd7ftx5o0PnMu4mq4NZvM_IE6uHiM8P5wn58v7i-vxjcfn5w6fzd5eFKWWVCik7wUBjUzUtNK3ecOCtNKztqrplhgnWINcCWsFNU7eWc4bMaGM2FYOy5uKEnO7z5oZ-zBiTGl00OAx6Qj9HVQshOefNQr56QPZ-DlMuTrEKSsmYqMtMsT1lgo8xoFW3wY067BQDteimepV1U4tuiyvrlmNeHjLP7Yjd34g7oTLw-gDomKdqg56Mi_ccF1DyimXu7Z7DPLGtw6CicTgZ7FxAk1Tn3X_LOHsQfSfjDe4w3nerIlegrpYFW_YLNgCNYF_Fb769zJU</recordid><startdate>2010</startdate><enddate>2010</enddate><creator>Harkness, James R., MD</creator><creator>Sabatine, Marc S., MD, MPH</creator><creator>Braunwald, Eugene, MD</creator><creator>Morrow, David A., MD, MPH</creator><creator>Sloan, Sarah, MS</creator><creator>Wiviott, Stephen D., MD</creator><creator>Giugliano, Robert P., MD, SM</creator><creator>Antman, Elliott M., MD</creator><creator>Cannon, Christopher P., MD</creator><creator>Scirica, Benjamin M., MD, MPH</creator><general>Mosby, Inc</general><general>Mosby</general><general>Elsevier Limited</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7QO</scope><scope>7RV</scope><scope>7TS</scope><scope>7X7</scope><scope>7XB</scope><scope>88C</scope><scope>88E</scope><scope>8AO</scope><scope>8C1</scope><scope>8FD</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>8G5</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AN0</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FR3</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>GUQSH</scope><scope>K9.</scope><scope>KB0</scope><scope>M0S</scope><scope>M0T</scope><scope>M1P</scope><scope>M2O</scope><scope>MBDVC</scope><scope>NAPCQ</scope><scope>P64</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>Q9U</scope><scope>7X8</scope></search><sort><creationdate>2010</creationdate><title>Extent of ST-segment resolution after fibrinolysis adds improved risk stratification to clinical risk score for ST-segment elevation myocardial infarction</title><author>Harkness, James R., MD ; Sabatine, Marc S., MD, MPH ; Braunwald, Eugene, MD ; Morrow, David A., MD, MPH ; Sloan, Sarah, MS ; Wiviott, Stephen D., MD ; Giugliano, Robert P., MD, SM ; Antman, Elliott M., MD ; Cannon, Christopher P., MD ; Scirica, Benjamin M., MD, MPH</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c465t-66d310ae858b08ba9202b6c1bd57b1c1318e2a30b32c87bf221e1cacc95104723</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2010</creationdate><topic>Adult</topic><topic>Aged</topic><topic>Angina pectoris</topic><topic>Aspirin</topic><topic>Biological and medical sciences</topic><topic>Blood pressure</topic><topic>Cardiology. Vascular system</topic><topic>Cardiovascular</topic><topic>Clinical outcomes</topic><topic>Confidence Intervals</topic><topic>Coronary Angiography</topic><topic>Coronary Circulation - drug effects</topic><topic>Coronary Circulation - physiology</topic><topic>Coronary heart disease</topic><topic>Diabetes</topic><topic>Dose-Response Relationship, Drug</topic><topic>Drug Administration Schedule</topic><topic>Electrocardiography</topic><topic>Female</topic><topic>Fibrinolysis - drug effects</topic><topic>Follow-Up Studies</topic><topic>Heart</topic><topic>Heart attacks</topic><topic>Heart failure</topic><topic>Humans</topic><topic>Hypertension</topic><topic>Male</topic><topic>Medical imaging</topic><topic>Medical sciences</topic><topic>Middle Aged</topic><topic>Mortality</topic><topic>Myocardial Infarction - diagnosis</topic><topic>Myocardial Infarction - drug therapy</topic><topic>Myocardial Infarction - mortality</topic><topic>Myocarditis. Cardiomyopathies</topic><topic>Odds Ratio</topic><topic>Platelet Aggregation Inhibitors - administration & dosage</topic><topic>Probability</topic><topic>Risk Assessment</topic><topic>Severity of Illness Index</topic><topic>Survival Analysis</topic><topic>Thrombolytic Therapy - methods</topic><topic>Ticlopidine - administration & dosage</topic><topic>Ticlopidine - analogs & derivatives</topic><topic>Time Factors</topic><topic>Treatment Outcome</topic><topic>Vascular Patency - drug effects</topic><topic>Veins & arteries</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Harkness, James R., MD</creatorcontrib><creatorcontrib>Sabatine, Marc S., MD, MPH</creatorcontrib><creatorcontrib>Braunwald, Eugene, MD</creatorcontrib><creatorcontrib>Morrow, David A., MD, MPH</creatorcontrib><creatorcontrib>Sloan, Sarah, MS</creatorcontrib><creatorcontrib>Wiviott, Stephen D., MD</creatorcontrib><creatorcontrib>Giugliano, Robert P., MD, SM</creatorcontrib><creatorcontrib>Antman, Elliott M., MD</creatorcontrib><creatorcontrib>Cannon, Christopher P., MD</creatorcontrib><creatorcontrib>Scirica, Benjamin M., MD, MPH</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Biotechnology Research Abstracts</collection><collection>Nursing & Allied Health Database</collection><collection>Physical Education Index</collection><collection>ProQuest_Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Healthcare Administration Database (Alumni)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Public Health Database</collection><collection>Technology Research Database</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>Research Library (Alumni Edition)</collection><collection>ProQuest Central (Alumni)</collection><collection>ProQuest Central</collection><collection>British Nursing Database</collection><collection>ProQuest Central Essentials</collection><collection>AUTh Library subscriptions: ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central</collection><collection>Engineering Research Database</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>Research Library Prep</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Database (Alumni Edition)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Healthcare Administration Database</collection><collection>Medical Database</collection><collection>ProQuest_Research Library</collection><collection>Research Library (Corporate)</collection><collection>Nursing & Allied Health Premium</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central Basic</collection><collection>MEDLINE - Academic</collection><jtitle>The American heart journal</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Harkness, James R., MD</au><au>Sabatine, Marc S., MD, MPH</au><au>Braunwald, Eugene, MD</au><au>Morrow, David A., MD, MPH</au><au>Sloan, Sarah, MS</au><au>Wiviott, Stephen D., MD</au><au>Giugliano, Robert P., MD, SM</au><au>Antman, Elliott M., MD</au><au>Cannon, Christopher P., MD</au><au>Scirica, Benjamin M., MD, MPH</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Extent of ST-segment resolution after fibrinolysis adds improved risk stratification to clinical risk score for ST-segment elevation myocardial infarction</atitle><jtitle>The American heart journal</jtitle><addtitle>Am Heart J</addtitle><date>2010</date><risdate>2010</risdate><volume>159</volume><issue>1</issue><spage>55</spage><epage>62</epage><pages>55-62</pages><issn>0002-8703</issn><eissn>1097-6744</eissn><coden>AHJOA2</coden><abstract>Background The TIMI risk score (TRS) for ST-segment elevation myocardial infarction (STEMI) is a convenient validated clinical risk score for predicting mortality. Although not part of the risk score, ST-segment resolution (STRes) may provide a simple method of risk stratification based on the response to reperfusion. We sought to determine whether STRes provides incremental risk stratification to the TIMI risk score. Methods The Clopidogrel as Adjunctive Reperfusion Therapy—Thrombolysis in Myocardial Infraction (CLARITY-TIMI 28) trial randomized STEMI patients receiving fibrinolysis to clopidogrel or placebo. A total of 2,340 patients had electrocardiograms (ECGs) valid to calculate STRes at 90 minutes, which was defined as complete (>70%), partial (30%-70%), or no resolution (30%). TRS was defined as low (0-2), medium (3-4), and high (≥5). Clinical follow-up was through 30 days. Results were validated in 2,743 patients from the ExTRACT-TIMI 25 study. Results The degree of STRes at 90 minutes after fibrinolysis correlated in a stepwise fashion with death or heart failure (5.1% complete STRes, 8.9% partial STRes, 13.4% no STRes, P < .001). Furthermore, the degree of STRes provided a consistent and significant gradient of risk across all risk score categories (low, medium, or high) and significantly improved the discriminatory ability of TIMI risk score to predict death or heart failure (c-statistic 0.69 for TIMI risk score alone and 0.74 with STRes added to the model, P < .001). With the inclusion of STRes to the TIMI risk score, 913 patients (39%) were reclassified to higher or lower risk groups, and the net reclassification improvement (NRI) was highly significant ( P < .001). In the ExTRACT-TIMI 25 trial, addition of the STRes improved also the c-statistic ( P = .012) and NRI ( P < .001). Conclusions The extent of STRes based on routinely obtained ECGs is an independent predictor of death and heart failure when used together with the TIMI risk score and significantly improves the ability to risk stratify patients after fibrinolysis.</abstract><cop>New York, NY</cop><pub>Mosby, Inc</pub><pmid>20102867</pmid><doi>10.1016/j.ahj.2009.10.033</doi><tpages>8</tpages></addata></record> |
fulltext | fulltext |
identifier | ISSN: 0002-8703 |
ispartof | The American heart journal, 2010, Vol.159 (1), p.55-62 |
issn | 0002-8703 1097-6744 |
language | eng |
recordid | cdi_proquest_miscellaneous_733622282 |
source | ScienceDirect Journals |
subjects | Adult Aged Angina pectoris Aspirin Biological and medical sciences Blood pressure Cardiology. Vascular system Cardiovascular Clinical outcomes Confidence Intervals Coronary Angiography Coronary Circulation - drug effects Coronary Circulation - physiology Coronary heart disease Diabetes Dose-Response Relationship, Drug Drug Administration Schedule Electrocardiography Female Fibrinolysis - drug effects Follow-Up Studies Heart Heart attacks Heart failure Humans Hypertension Male Medical imaging Medical sciences Middle Aged Mortality Myocardial Infarction - diagnosis Myocardial Infarction - drug therapy Myocardial Infarction - mortality Myocarditis. Cardiomyopathies Odds Ratio Platelet Aggregation Inhibitors - administration & dosage Probability Risk Assessment Severity of Illness Index Survival Analysis Thrombolytic Therapy - methods Ticlopidine - administration & dosage Ticlopidine - analogs & derivatives Time Factors Treatment Outcome Vascular Patency - drug effects Veins & arteries |
title | Extent of ST-segment resolution after fibrinolysis adds improved risk stratification to clinical risk score for ST-segment elevation myocardial infarction |
url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-29T02%3A26%3A57IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Extent%20of%20ST-segment%20resolution%20after%20fibrinolysis%20adds%20improved%20risk%20stratification%20to%20clinical%20risk%20score%20for%20ST-segment%20elevation%20myocardial%20infarction&rft.jtitle=The%20American%20heart%20journal&rft.au=Harkness,%20James%20R.,%20MD&rft.date=2010&rft.volume=159&rft.issue=1&rft.spage=55&rft.epage=62&rft.pages=55-62&rft.issn=0002-8703&rft.eissn=1097-6744&rft.coden=AHJOA2&rft_id=info:doi/10.1016/j.ahj.2009.10.033&rft_dat=%3Cproquest_cross%3E3238257731%3C/proquest_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c465t-66d310ae858b08ba9202b6c1bd57b1c1318e2a30b32c87bf221e1cacc95104723%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=1504611374&rft_id=info:pmid/20102867&rfr_iscdi=true |